<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01186185</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00006240</org_study_id>
    <nct_id>NCT01186185</nct_id>
  </id_info>
  <brief_title>Fludrocortisone for Sudden Hearing Loss</brief_title>
  <official_title>Mineralocorticoid Treatment for Sudden Sensorineural Hearing Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard of care treatment of sudden hearing loss uses a type of steroid called
      glucocorticoid. Examples of glucocorticoids are prednisone, methylprednisolone and
      dexamethasone. Not everybody recovers hearing with glucocorticoid treatment. Fludrocortisone
      is a different type of steroid called mineralocorticoid. Unlike glucocorticoids, which work
      by reducing inflammation, mineralocorticoids work by changing salt and fluid balance. In
      animal studies, fludrocortisone is at least as effective as glucocorticoid in preserving
      hearing. Fludrocortisone is not approved for the treatment of sudden hearing loss. The
      purpose of this study is to test whether fludrocortisone can treat sudden hearing loss.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hearing</measure>
    <time_frame>At one month</time_frame>
    <description>Hearing outcome will be determine by pure-tone and speech audiometry measured at the completion of a one-month course of treatment and compared with pre-treatment test results.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hearing Loss, Sensorineural</condition>
  <arm_group>
    <arm_group_label>Fludrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludrocortisone</intervention_name>
    <description>Fludrocortisone 0.2 mg by mouth daily for 30 days</description>
    <arm_group_label>Fludrocortisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Idiopathic sudden sensorineural hearing loss within 3 months

          -  Failure to recover hearing with glucocorticoid treatment or inability to tolerate
             glucocorticoid

        Exclusion Criteria:

          -  Other diagnosis for the sudden hearing loss

          -  Concurrent systemic use of another steroid

          -  Hypersensitivity to fludrocortisone

          -  Systemic fungal infection

          -  Hypertension requiring two or more medications

          -  Pitting edema

          -  Cardiomegaly

          -  Congestive heart failure

          -  Electrolyte abnormality

          -  Concurrent use of barbiturates, phenytoin, fosphenytoin, rifampin, or rifapentine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anh Nguyen-Huynh, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anh Nguyen-Huynh, MD PhD</last_name>
    <phone>503-494-8135</phone>
    <email>nguyanh@ohsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anh Nguyen-Huynh</last_name>
      <phone>503-260-9192</phone>
      <email>nguyanh@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Anh Nguyen-Huynh, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2010</study_first_submitted>
  <study_first_submitted_qc>August 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2010</study_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Anh Nguyen-Huynh</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>sudden</keyword>
  <keyword>sensorineural</keyword>
  <keyword>hearing loss</keyword>
  <keyword>fludrocortisone</keyword>
  <keyword>mineralocorticoid</keyword>
  <keyword>steroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludrocortisone</mesh_term>
    <mesh_term>Mineralocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

